Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
Details : Anagrelide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2017
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anagrelide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thrombocytosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2014
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Anagrelide Retard in Essential Thrombocythemia
Details : Anagrelide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 04, 2014
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
Details : Anagrelide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 13, 2012
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Details : Anagrelide HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2011
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anagrelide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2010
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anagrelide HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2010
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anagrelide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 09, 2010
Lead Product(s) : Anagrelide Hydrochloride
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
